# US 2006/0051419 A1 · Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051419 A1
- Document ID: US20060051419A1
- Status: Published application
- Kind: A1
- Application number: 11/202,689
- Filed: 2005-08-12
- Published: 2006-03-09
- Earliest claimed: 2004-08-13
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Thomas Friedl; Rolf-Stefan Brickl
- Web page: https://patentgrep.com/patent/US20060051419A1

## CPC

- A61K 9/5078: {with drug-free core}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

## Claims

### Claim 1

An extended release pellet comprising pramipexole or a pharmaceutically acceptable salt thereof, and at least one release-modifying excipient.

### Claim 2 (depends on 1)

The extended release pellet according to claim 1, wherein the pramipexole or the pharmaceutically acceptable salt thereof is embedded within a matrix formed by at least one release-modifying excipient.

### Claim 3 (depends on 1)

The extended release pellet according to claim 1, wherein at least one of the release-modifying excipients is a lipid, wax, or water-insoluble polymer.

### Claim 4 (depends on 1)

The extended release pellet according to claim 1, comprising a core and a coating, wherein at least one release-modifying excipient is incorporated in the coating.

### Claim 5 (depends on 4)

The extended release pellet according to claim 4, wherein the pramipexole or the pharmaceutically acceptable salt thereof is incorporated in the core.

### Claim 6 (depends on 4)

The extended release pellet according to claim 4, wherein the coating comprises at least a first layer and a second layer surrounding the first layer, wherein the first layer comprises the pramipexole or the pharmaceutically acceptable salt thereof, and wherein the second layer comprises at least one release-modifying excipient.

### Claim 7 (depends on 6)

The extended release pellet according to claim 6, wherein at least one release-modifying excipient is ethyl cellulose, cellulose acetate, polyvinylacetate, polyacrylate, polymethacrylate, or ammonio methacrylate copolymer.

### Claim 8 (depends on 7)

The extended release pellet according to claim 7, wherein the second layer further comprises at least one water-soluble excipient.

### Claim 9 (depends on 8)

The extended release pellet according to claim 8, wherein at least one water-soluble excipient is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, and polyethylene glycol.

### Claim 10 (depends on 7)

The extended release pellet according to claim 7, wherein the second layer further comprises an enteric coating polymer.

### Claim 11 (depends on 8)

The extended release pellet according to claim 8, wherein enteric coating polymer is methacrylic acid copolymers type A and B.

### Claim 12 (depends on 10)

The extended release pellet according to claim 10, wherein the second layer comprises from about 10 to about 85 wt.-% of the enteric coating polymer and from about 15 to about 75 wt.-% of the water-insoluble polymer.

### Claim 13 (depends on 6)

The extended release pellet according to claim 6, wherein the core comprises a saccharide.

### Claim 14 (depends on 13)

The extended release pellet according to claim 13, wherein the saccharide is saccharose, starch, cellulose, or a cellulose derivative.

### Claim 15 (depends on 14)

The extended release pellet according to claim 14, wherein the saccharide is microcrystalline cellulose.

### Claim 16

An extended release pellet comprising:
(1) an inert pellet core;
(2) a first layer comprising pramipexole or a pharmaceutically acceptable salt thereof; and
(3) a second layer provided on the first layer, the second layer being an extended release coating comprising:
(a) at least one water-insoluble polymer and optionally a pore former, the resulting pellet having a pH-independent in vitro release characteristic, or
(b) a mixture of a pH-dependent enteric-coating polymer and a pH-independently water swelling polymer,
wherein the extended release pellet has a close to zero order in vitro release characteristic at acidic pH values up to pH 6.8, an accelerated release above pH 6.8, and a more accelerated release above pH 7.3.

### Claim 17 (depends on 16)

The extended release pellet according to claim 16, wherein the first layer further comprises one or more wet binders and further excipients.

### Claim 18 (depends on 16)

The extended release pellet according to claim 16, wherein the inert pellet core comprises polysaccharides, cellulose, a cellulose derivative, starch, and/or waxes.

### Claim 19 (depends on 16)

The extended release pellet according to claim 16, wherein the inert pellet core comprises saccharose and/or microcrystalline cellulose.

### Claim 20 (depends on 16)

The extended release pellet according to claim 16, wherein the water-insoluble polymer is ethyl cellulose, cellulose acetate, polyvinylacetate, or polyacrylates and derivatives thereof.

### Claim 21 (depends on 16)

The extended release pellet according to claim 16, wherein the pH-dependent enteric-coating polymer is an anionic carboxylic acrylic polymer soluble above a pH value of 5.5.

### Claim 22 (depends on 21)

The extended release pellet according to claim 21, wherein the pH-dependent enteric-coating polymer is soluble above a pH value of 7.0.

### Claim 23 (depends on 21)

The extended release pellet according to claim 21, wherein the pH-dependent enteric-coating polymer is a partly methyl esterified methacrylic acid polymer.

### Claim 24 (depends on 16)

The extended release pellet according to claim 16, wherein the pH-independently water swelling polymer is a quaternary ammonium substituted acrylic polymer.

### Claim 25 (depends on 24)

The extended release pellet according to claim 24, wherein the quaternary ammonium substituted acrylic polymer has an ammonium substitution of about 5 to about 10 per cent by weight.

### Claim 26 (depends on 16)

The extended release pellet according to claim 16, wherein the pH-dependent enteric-coating polymer is present in an amount of 10 to 85% by weight of the coating and the pH-independently water swelling polymer is present in an amount of 15 to 75% by weight of the coating.

### Claim 27 (depends on 21)

The extended release pellet according to claim 21, wherein the pH-dependent enteric-coating polymer is present in an amount of 10 to 85% by weight of the coating and the pH-independently water swelling polymer is present in an amount of 15 to 75% by weight of the coating.

### Claim 28 (depends on 24)

The extended release pellet according to claim 24, wherein the pH-dependent enteric-coating polymer is present in an amount of 10 to 85% by weight of the coating and the pH-independently water swelling polymer is present in an amount of 15 to 75% by weight of the coating.

### Claim 29 (depends on 16)

The extended release pellet according to claim 16, comprising:
(1) an inert pellet core;
(2) a first layer comprising pramipexole or a pharmaceutically acceptable salt thereof; and
(3) a second layer provided on the first layer, the second layer being an extended release coating comprising a mixture of:
(i) a pH-dependent enteric-coating polymer,
(ii) a pH-independently water swelling polymer, and
(iii) a pore-forming component,
wherein the extended release pellet has a close to zero order in vitro release characteristic at acidic pH values up to pH 6.8, an accelerated release above pH 6.8, and a more accelerated release above pH 7.3.

### Claim 30 (depends on 29)

The extended release pellet according to claim 29, wherein the pore-forming component is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, or polyethylene glycol.

### Claim 31

An extended release pellet comprising pramipexole or a pharmaceutically acceptable salt thereof prepared by wet or melt extrusion or melt granulation using excipients achieving extended release without a further diffusion membrane.

### Claim 32

A method of manufacturing extended release pellets, the method comprising the steps of:
(1) providing an inert starter pellet core;
(2) applying a solution or dispersion of a first coating composition comprising pramipexole or a pharmaceutically acceptable salt thereof, at least a binder, and optionally excipient(s) onto the inert starter pellet core, wherein the pramipexole or a pharmaceutically acceptable salt thereof is used as unmilled material dissolved/dispersed in a solvent together with the binder(s) and optional excipient(s), and subsequently drying the first coated pellet;
(3) applying a solution or dispersion of a second coating composition as functional coating composition onto the first coated pellet obtained in step (2), wherein the coating composition comprises (a) at least one water-insoluble polymer and optionally a pore former or (b) a mixture of a pH-dependent enteric-coating polymer and a pH-independently water swelling polymer, and optional excipient(s), and a solvent, and subsequently drying the obtained extended release pellet.

### Claim 33 (depends on 32)

The method according to claim 32, further comprising performing manual screening after step (2) and/or step (3) in order to remove agglomerates.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the applying the first coating composition of step (2) is done by spraying the solution or dispersion of the first coating composition onto the inert starter pellet core.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the applying the second coating composition of step (3) is done by spraying the solution or dispersion of the second coating composition onto the first coated pellet.

### Claim 36 (depends on 1)

A capsule containing extended release pellets according to claim 1.

### Claim 37 (depends on 16)

A capsule containing extended release pellets according to claim 16.

### Claim 38 (depends on 36)

The capsule according to claim 36, wherein the capsule contains an amount of extended release pellets sufficient to provide an effective daily dose of pramipexole or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 37)

The capsule according to claim 37, wherein the capsule contains an amount of extended release pellets sufficient to provide an effective daily dose of pramipexole or a pharmaceutically acceptable salt thereof.
